Current/ Expected Orderbook/ Pending Orders?

Vimta Labs does not disclose specific details about its order book. When asked about the order book size and execution timeframe, the management stated they do not share these specifics. Despite this, the company expressed confidence that the order books are larger currently than in previous quarters. Management highlighted that external factors have temporarily impacted some segments but indicated order books remain robust. They emphasized long-term contracts from customers supporting future growth. Overall, while specific order book numbers are not shared, the management is optimistic about

Any current/future new fundraising through debt or equity?

As of September 30, 2023, Vimta Labs has an outstanding loan book of Rs. 19 crores (Rs. 12.5 crores of term loan and Rs. 6.5 crores of working capital utilization). The company maintains a net debt-free balance sheet with cash and cash equivalents totaling Rs. 262 million. CAPEX for FY24 is guided at Rs. 90 crores (Rs. 900 million), primarily for expansion and routine equipment spend. There is no mention of any planned new fundraising via debt or equity in the discussion. The CFO and MD indicated ongoing investments funded through routine capital expenditure and depreciation, with no specifics

Any current/future capex/capital investment/strategic investment?

The CAPEX planned for the current year was Rs. 90 crores. CAPEX for a capacity expansion of this size is typically planned over at least five years. Equipment purchased is part of routine business operations. Future CAPEX mainly includes expansion and routine capital expenditure related to equipment. Routine spending will typically be around the depreciation amount. Future CAPEX may increase if exciting customer partnerships develop, but no specific numbers are available yet. CAPEX guidance for FY24 remains at Rs. 900 million (Rs. 90 crores). New capabilities and building expansions planned to

Future growth expectations in sales/revenue/volumes?

Vimta Labs sees current market growth constrained by regulatory and implementation delays, especially in pharma and food segments. Long-term confidence in revenue growth remains strong; target of Rs. 500 crore by FY26. Growth in pharma expected to revive post temporary setbacks; delays in DCGI approvals impacting short-term sales. Electrical and Electronics (E&E) segment showing strong quarter-on-quarter growth, driven by government push on "Make in India" and defense sourcing mandates. Capacity expansion to be completed by March 2024, likely boosting revenue potential. Domestic market growth

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth in H2 FY24 is expected to be better than H1, with margins potentially improving to around 29% (Q2 & Q1 level or slightly better). Temporary headwinds like delays in DCGI approvals and deferment of pharma projects are expected to ease with corrective actions underway. The company remains confident of delivering overall growth in FY24 despite near-term challenges. Long-term revenue target is Rs. 500 crores by FY26, implying steep annual growth of around 25% needed from FY25 onward. Expansion activities nearing completion by March 2024 will enable higher revenue. Strong growth from electro

Vimta Labs LtdQ2 FY24Healthcare Services

Vimta Labs Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹584P/E: 33.1Market Cap: ₹2.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Vimta Labs sees current market growth constrained by regulatory and implementation delays, especially in pharma and food segments.
Long-term confidence in revenue growth remains strong; target of Rs. 500 crore by FY26.
Growth in pharma expected to revive post temporary setbacks; delays in DCGI approvals impacting short-term sales.
Electrical and Electronics (E&E) segment showing strong quarter-on-quarter growth, driven by government push on "Make in India" and defense sourcing mandates.
Capacity expansion to be completed by March 2024, likely boosting revenue potential.
Domestic market growth and new customer partnerships anticipated to support higher revenues.
Overall, expect a bounce back in H2 FY24 with margins potentially rising to 28-29%.
Short-term growth rates currently challenging; clearer visibility expected by January 2024.

Margin guidance

Category 3

Growth in H2 FY24 is expected to be better than H1, with margins potentially improving to around 29% (Q2 & Q1 level or slightly better).
Temporary headwinds like delays in DCGI approvals and deferment of pharma projects are expected to ease with corrective actions underway.
The company remains confident of delivering overall growth in FY24 despite near-term challenges.
Long-term revenue target is Rs. 500 crores by FY26, implying steep annual growth of around 25% needed from FY25 onward.
Expansion activities nearing completion by March 2024 will enable higher revenue.
Strong growth from electronics segment and stable environment and diagnostics businesses support growth expectations.
Operating leverage will improve as revenue recovers leading to margin expansion.
Order book size is stable or improving though exact details not disclosed.

See what Vimta Labs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

As of September 30, 2023, Vimta Labs has an outstanding loan book of Rs. 19 crores (Rs. 12.5 crores of term loan and Rs. 6.5 crores of working capital utilization).
The company maintains a net debt-free balance sheet with cash and cash equivalents totaling Rs. 262 million.
CAPEX for FY24 is guided at Rs. 90 crores (Rs. 900 million), primarily for expansion and routine equipment spend.
There is no mention of any planned new fundraising via debt or equity in the discussion.
The CFO and MD indicated ongoing investments funded through routine capital expenditure and depreciation, with no specifics on fresh capital raising.
The focus appears to be on organic growth and capacity expansion without external fundraising at present.

Order book

Vimta Labs does not disclose specific details about its order book.
When asked about the order book size and execution timeframe, the management stated they do not share these specifics.
Despite this, the company expressed confidence that the order books are larger currently than in previous quarters.
Management highlighted that external factors have temporarily impacted some segments but indicated order books remain robust.
They emphasized long-term contracts from customers supporting future growth.
Overall, while specific order book numbers are not shared, the management is optimistic about future revenue growth based on existing contracts.

See what Vimta Labs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The CAPEX planned for the current year was Rs. 90 crores.
CAPEX for a capacity expansion of this size is typically planned over at least five years.
Equipment purchased is part of routine business operations.
Future CAPEX mainly includes expansion and routine capital expenditure related to equipment.
Routine spending will typically be around the depreciation amount.
Future CAPEX may increase if exciting customer partnerships develop, but no specific numbers are available yet.
CAPEX guidance for FY24 remains at Rs. 900 million (Rs. 90 crores).
New capabilities and building expansions planned to be commissioned by March to support higher revenue growth.

Track Vimta Labs Ltd — get its next earnings analysis in your feed

How does Vimta Labs Ltd rank vs peers in Healthcare Services?

Pro feature

ThisVimta Labs Ltd

Rev 3Mar 3

See where Vimta Labs Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vimta Labs Ltd rank in Healthcare Services?

Compare Vimta Labs Ltd against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vimta Labs Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vimta Labs Ltd Q2 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vimta Labs Ltd rank in Healthcare Services?

Continue your research

What Vimta Labs Ltd's management said in earlier quarters

Others in Healthcare Services this season